Maintenance Therapy in Transplant-Ineligible NDMM
Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.
EP: 1.Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP: 2.Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP: 3.Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP: 4.Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP: 5.Treating Patients with High-Risk NDMM
EP: 6.Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
EP: 7.Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
EP: 8.Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP: 9.Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
Now Viewing
EP: 10.Maintenance Therapy in Transplant-Ineligible NDMM
EP: 11.Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 12.Bispecific Antibodies in the Treatment of R/R MM
EP: 13.CAR-T Therapy in R/R MM Treatment
EP: 14.Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP: 15.Sequencing Therapies in Patients with R/R MM
EP: 16.Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP: 17.Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
